Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
February 10, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
January 20, 2021 08:45 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Announces Pricing of Public Offering of Common Stock

WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
January 19, 2021 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Announces Proposed Public Offering of Common Stock

WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
January 19, 2021 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Durable Clinical Activity over 12 Weeks was DemonstratedData Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid ArthritisATI-450, an...
December 15, 2020 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

New Scientific Advisory Board of Immuno-Inflammatory ExpertsPreliminary Topline Data for the ATI-450-RA-201 Trial Expected in January 2021 WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris...
November 16, 2020 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
November 04, 2020 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisInitiated Phase 2a Trial of ATI-450, an...
October 20, 2020 07:00 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
September 01, 2020 16:01 ET | Source: Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...